Journal Mobile Options
Table of Contents
Vol. 69, No. 4, 2010
Issue release date: June 2010
Gynecol Obstet Invest 2010;69:274–280
(DOI:10.1159/000277640)

Prevalence of Polycystic Ovary Syndrome and Related Disorders in Mexican Women

Moran C. · Tena G. · Moran S. · Ruiz P. · Reyna R. · Duque X.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background/Aims: Polycystic ovary syndrome (PCOS) has been found to affect 4–8% of women of reproductive age; however, in Mexican-Americans a prevalence of 12.8% has been reported. This study determines the prevalence of PCOS in a sample of Mexican women. Methods: This prospective cross-sectional study included 150 female Mexican volunteers aged 20–45 years. Menstrual cycles were recorded and hirsutism was graded. Pelvic ultrasound was performed and androgen levels were measured. PCOS was diagnosed by hyperandrogenism and/or hyperandrogenemia, and oligo-ovulation (NIH 1990 criteria), and also by 2 of 3 findings: oligo-ovulation, clinical and/or biochemical hyperandrogenism and polycystic ovaries (PCO) (Rotterdam 2003 criteria), excluding other disorders. Results: Nine of the 150 women were diagnosed with PCOS, a prevalence of 6.0% (95% CI: 1.9–10.1%), according to NIH criteria. The ultrasound morphology added one patient to give ten PCOS patients, a prevalence of 6.6% (95% CI: 2.3–10.9%) according to Rotterdam criteria. All PCOS patients presented oligo-ovulation, 9 had hirsutism and 7 of them had acne. Eight of the 10 PCOS patients had morphologic characteristics of PCO. Conclusion: The prevalence of PCOS in Mexican women is approximately 6.0%, similar to other populations, but lower than 12.8% reported in Mexican-American women.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R: Prevalence of the polycystic ovary syndrome in unselected Black and White women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998;83:3078–3082.
  2. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapanti ED, Bartzis MI: A survey of the polycystic ovary syndrome in the Greek Island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999;84:4006–4011.
  3. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF: A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000;85:2434–2438.
  4. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO: The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745–2749.
  5. Moran C, Tapia MC, Hernandez E, Vazquez G, Garcia Hernandez E, Bermudez JA: Etiological review of hirsutism in 250 patients. Arch Med Res 1994;25:311–314.
  6. Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, Taylor K, Boots LR: Androgen excess in women: experience with over 1,000 consecutive patients. J Clin Endocrinol Metab 2004;89:453–462.
  7. Carmina E, Rosato F, Janni A, Rizzo M, Longo RA: Relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab 2006;91:2–6.
  8. Goodarzi MO, Quiñones MJ, Azziz R, Rotter JI, Hsueh WA, Yang H: Polycysytic ovary syndrome in Mexican-Americans: prevalence and association with the severity of insulin resistance. Fertil Steril 2005;84:766–769.
  9. Zawadzki JK, Dunaif A: Diagnostic criteria for polycystic ovary syndrome: towards a rational approach; in Dunaif A, Givens JR, Haseltine F, Merriam GR (eds): Polycystic Ovary Syndrome. Boston, Blackwell, 1992, pp 377–384.
  10. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19–24.
  11. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF: The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009;91:456–488.
  12. Legro RS, Kunselman AR, Dodson WC, Dunaif A: Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165–169.
  13. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J: Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141–146.
  14. WHO Expert Committee: Physical Status: The Use and Interpretation of Anthropometry. WHO Tec Rep Ser No. 854. Geneva, WHO, 1995.
  15. Moran C, Hernandez E, Ruiz JE, Fonseca ME, Bermudez JA, Zarate A: Upper body obesity and hyperinsulinemia are associated with anovulation. Gynecol Obstet Invest 1999;47:1–5.
  16. Ferriman D, Gallwey JD: Clinical assessment of body hair growth in women. J Clin Endocr 1961;21:1440–1447.
  17. Hatch R, Rosenfield RL, Kim MH, Tredway D: Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 1981;140:815–830.
  18. Whitley E, Ball J: Statistics review 2: samples and populations. Crit Care 2002;6:143–148.
  19. Bland JM, Altman DG: Transforming data. Statistics notes. BMJ 1996;312:770.
  20. Moran C, Azziz R, Weintrob N, Witchel S,Rohmer V, Dewailly D, Marcondes JAM, Pugeat M, Speiser PW, Pignatelli D, Mendonca BB, Bachega TAS, Escobar-Morreale HF, Carmina E, Fruzzetti F, Kelestimur F: Reproductive outcome of women with 21-hydroxylase deficient nonclassic adrenal hyperplasia. J Clin Endocrinol Metab 2006;91:3451–3456.
  21. American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2008;31:S62–S67.

    External Resources

  22. Legro RS, Castracane VD, Kauffman RP: Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv 2004;59:141–154.
  23. Dewailly D: The role of pelvic sonography in the polycystic ovary syndrome. Androgen Excess Soc Bull 2005;3:1–4.
  24. Polson DW, Adams J, Wadsworth J, Franks S: Polycystic ovaries: a common finding in normal women. Lancet 1988;i:870–872.

    External Resources

  25. Koivunen R, Laatikainen T, Tomas C, Huhtaniemi I, Tapanainen J, Martikainen H: The prevalence of polycystic ovaries in healthy women. Acta Obstet Gynecol Scand 1999;78:137–141.
  26. Farquhar CM, Birdsall M, Manning P, Mitchell JM, France JT: The prevalence of polycystic ovaries on ultrasound scanning on a population of randomly selected women. Aust NZ J Obstet Gynecol 1994;34:67–72.
  27. Romaguera J, Moran C, Diaz-Montes TP, Hines GA, Cruz RI, Azzis R: Prevalence of 21-hydroxylase-deficient nonclassic adrenal hyperplasia and insulin resistance among hirsute women from Puerto Rico. Fertil Steril 2000;74:59–62.
  28. Rivolta G, Cerutti R, Colombo R, Miano G, Dionisio P, Grossi E: Prevalence of subclinical hypothyroidism in a population living in the Milan metropolitan area. J Endocrinol Invest 1999;22:693–697.
  29. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE: Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002;87:489–499.
  30. Josimovich JB, Lavenhar MA, Devanesan MM, Sesta HJ, Wilchins SA, Smith AC: Heterogeneous distribution of serum prolactin values in apparently healthy young women, and the effects of oral contraceptive medication. Fertil Steril 1987;47:785–791.
  31. Biller BM, Luciano A, Crosignani PG, Molitch M, Olive D, Rebar R, Sanfilippo J, Webster J, Zacur H: Guidelines for the diagnosis and treatment of hyperprolactinemia. J Reprod Med 1999;44(suppl 12):1075–1084.
  32. Kauffman RP, Baker VM, DiMarino P, Gimpel T, Castracane VD: Polycystic ovarian syndrome and insulin resistance in White and Mexican American women: a comparison of two distinct populations. Am J Obstet Gynecol 2002;187:1362–1369.
  33. Secretaría de Salud: Encuesta Nacional de Enfermedades Crónicas. México, 1993. Diabetes mellitus. Cap. 3, pág. 10–15.
  34. Olaiz-Fernandez G, Rojas R, Aguilar-Salinas CA, Rauda J, Villalpando S: Diabetes mellitus in Mexican adults: results from the 2000 National Health Survey. Salud Publica Mex 2007;49(suppl 3):s331–s337.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50